Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

GLP-1 Drugs

Eli Lilly's GLP‑1 Surge Leaves Pfizer as the High‑Yield Option

The contrast forces investors to weigh Lilly's rapid GLP‑1-driven capital gains against Pfizer's large dividend that prices in looming patent and revenue risk.

46 ARTICLES

4mo ago

Novo Nordisk Forecasts Up to 13% 2026 Sales and Profit Decline as U.S. Price Cuts Bite

6 ARTICLES

5mo ago

Eli Lilly’s GLP-1 Lead Faces New Pressure From Novo’s Weight-Loss Pill

53 ARTICLES

5mo ago

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

7 ARTICLES

6mo ago

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

45 ARTICLES

6mo ago

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

17 ARTICLES

6mo ago

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

59 ARTICLES

7mo ago

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

17 ARTICLES

7mo ago

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

7 ARTICLES

10mo ago

GLP-1 Drugs Linked to Lower Overall Cancer Risk in JAMA Oncology Analysis